NSE: DIVISLAB | BSE: 532488

Expensive Star

Download real time

6087.00 -21.00 (-0.34%)

New 52W High in past week

496.5K NSE+BSE Volume

NSE 30 Apr, 2025 3:51 PM (IST)

161,590.7

Market Cap

Market Runner Up

0.7

Beta 1Year

Very Low volatility

Divi's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DIVISLAB, BSE:532488 Divi's Laboratories Ltd.

Divi's Laboratories Ltd.

01 Mar 2021

6087.00

-0.34%

Ashika - Stock Picks Divis laboratories Ltd. - March 2021

Buy: Divi's Laboratories Ltd.

Target

Ashika Research

Divi's Laboratories Ltd. has gained 52.59% in the last 1 Year

Divi's Laboratories Ltd.

15 Feb 2021

6087.00

-0.34%

The growth was driven across generic APIs and CRAMS businesses. Strong positioning of divis will help in monetizing the growth opportunity in API and CRAMS space given its stellar execution track record and being one of the preferred suppliers. Further, recently done and...

Divi's Laboratories Ltd. has gained 52.59% in the last 1 Year

Divi's Laboratories Ltd.

10 Feb 2021

6087.00

-0.34%

DIVI' S LAB

Buy: Divi's Laboratories Ltd.

Geojit BNP Paribas

Divi's Laboratories Limited is engaged in the manufacturing and selling of generic active pharmaceutical ingredients (APIs) and intermediates in the United States, Asia and Europe. Its manufacturing and research and...

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

07 Feb 2021

6087.00

-0.34%

On a stellar growth trajectory

Buy: Divi's Laboratories Ltd.

Target

Motilal Oswal

Divi's Labs (DIVI) reported in-line 3QFY21 earnings. This was led by healthy traction in Generics / Custom Synthesis (CS), coupled with lower raw material cost, driven by process improvements. Meaningful benefit is yet to accrue from the major capex phase. 10 new molecules under development in generic APIs and contrast media APIs would provide a fillip going forward. We maintain our earnings estimate for FY21/FY22/FY23 and roll forward our Target Price to INR4,530, valuing DIVI at 36x 12M forward earnings. We remain positive on DIVI on the back of a) sustained volume growth in the...

Divi's Laboratories .. has an average target of 5832.12 from 9 brokers.

Divi's Laboratories Ltd.

06 Feb 2021

6087.00

-0.34%

Divi's Laboratories

Buy: Divi's Laboratories Ltd.

Target

ICICI Securities Limited

The company remains committed to a few research driven niche opportunities as was the case when it started commercial operations. Two generics, Naproxen (pain management) and Dextromethorphan (cough suppressant) account for ~26% of overall revenues. Divi's enjoys ~70% global market share in these two products. Divi's is also increasing its presence in another niche area of carotenoids after acquiring requisite capabilities. It has developed various types of carotenoids including betacarotene. Recent supply constraints from China are likely to propel growth in this segment. With focus on brownfield expansion, the management is...

Number of FII/FPI investors increased from 826 to 922 in Mar 2025 qtr.

Divi's Laboratories Ltd.

30 Dec 2020, 12:00AM

6087.00

-0.34%

Divi's Laboratories

Buy: Divi's Laboratories Ltd.

Target

ICICI Securities Limited

More than strong half-yearly performance (the management stresses that in a business like this can be lumpy) important narrative for Divi's is unprecedented capex to further augment capacities besides preparing for growing opportunities arising due to China plus one factor. It has earmarked an aggressive capex of ~| 3700 crore [| 1800 (existing plans) + | 400 (custom synthesis blocks) + | 1500 (greenfield Kakinada plant) crore], over and above ~| 2000 crore spent in last five years. Divi's remains a quintessential play on the Indian API/CRAMs segment with its product...

Divi's Laboratories .. has an average target of 5832.12 from 9 brokers.

Divi's Laboratories Ltd.

20 Nov 2020

6087.00

-0.34%

Earnings Wrap

Buy: Divi's Laboratories Ltd.

Recommendation Target

ICICI Securities Limited

Corporate earnings in Q2FY21 came in better-than-expected wherein companies benefitted from low raw material cost and realised operating leverage benefits with management commentary positive on pace of demand recovery and retaining some part of operating leverage gains in the post Covid world. At the index level, excluding the BFSI space; net sales fell ~10% YoY, primarily driven by double digit topline decline in the oil & gas space. On the profitability front, EBITDA margins at the index level came in at a multi-quarter high at 18.9%, up...

Divi's Laboratories .. has an average target of 5832.12 from 9 brokers.

Divi's Laboratories Ltd.

17 Nov 2020

6087.00

-0.34%

Divis Laboratories Limited

Divi's Laboratories Ltd.

SMC online

Number of FII/FPI investors increased from 826 to 922 in Mar 2025 qtr.

Divi's Laboratories Ltd.

08 Nov 2020

6087.00

-0.34%

Another quarter of remarkable performance

Buy: Divi's Laboratories Ltd.

Target

Motilal Oswal

Divi's Lab (DIVI) reported a strong beat on 2QFY21 earnings. This was led by healthy traction in Generics / Custom Synthesis (CS), coupled with lower raw material cost and better operating leverage. Interestingly, meaningful benefit is yet to accrue from the major capex phase. DIVI indicated an...

Divi's Laboratories .. has an average target of 5832.12 from 9 brokers.

Is Divi's Laboratories Ltd. worth buying?

745 Votes:

Buy 78.12%

Sell 14.9%

Hold 6.98%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf